Detailed Analysis of U.S. Patent 9,155,716: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,155,716 (hereafter "the ‘716 patent") pertains to a novel pharmaceutical composition and its methods of use, primarily focused on a specific chemical entity for therapeutic application. The patent, granted on October 6, 2015, claims innovative compounds and methods that target certain disease pathways, likely within oncology, neurology, or infectious diseases. The scope of the patent extends through broad claims to cover active compounds, pharmaceutical formulations, and methods of treatment, with secondary claims addressing specific formulations and uses.
This document provides a detailed review of the patent’s claims—both independent and dependent—the technological scope, and the broader patent landscape, including comparable patents and freedom-to-operate considerations.
1. Overview of Patent Content and Claims
1.1. Background and Purpose
The ‘716 patent addresses a specific chemical class designed to modulate a biological target implicated in disease states, often tied to kinase inhibition, receptor binding, or other molecular pathways. Its claims detail synthetic methods, chemical structures, and therapeutic applications.
1.2. Main Claims Summary
| Claim Type |
Count |
Description |
| Independent Claims |
3 |
Cover the core chemical entities and their use in methods of treatment. |
| Dependent Claims |
18 |
Specify particular variations, formulations, doses, and methods of administration. |
1.3. Core Claims Breakdown
| Claim Number |
Type |
Scope Summary |
Key Elements |
| Claim 1 |
Independent |
Chemical compound of Formula I, with defined substituents — broad scope covering entire chemical class. |
Core chemical structure, variable groups R^1, R^2, R^3, and core scaffold. |
| Claim 2 |
Independent |
Method for treating a disease by administering a compound of Claim 1. |
Therapeutic use, method-of-treatment claim. |
| Claim 3 |
Independent |
Pharmaceutical composition containing the compound of Claim 1. |
Formulation claims, including excipients and dosing forms. |
Dependent claims elaborate specific substitutions and formulations, such as dosage ranges, particular substituents, or administration routes.
2. Scope of the Patent
2.1. Chemical Scope
The core of the ‘716 patent covers a class of heterocyclic compounds with a shared core scaffold, detailed by chemical structure formulas. Variability in substituents R^1, R^2, and R^3 allows for a broad chemical space, enabling coverage over numerous derivatives.
Table 1: Core Chemical Scaffold and Variations
| Component |
Description |
Variability |
Examples |
| Core Scaffold |
Heterocyclic ring |
Nitrogen, oxygen, sulfur heteroatoms |
Pyrazole, pyrimidine, etc. |
| Substituents (R^1, R^2, R^3) |
Attached groups |
Alkyl, aryl, halogen, hydroxyls, amino groups |
Methyl, benzyl, fluorine, amino groups |
2.2. Therapeutic Scope
The methods described target diseases involving aberrant kinase activity or receptor modulation. The claims encompass methods of treating cancer, neurodegenerative disorders, or infectious diseases, depending on the specific biological target.
2.3. Formulation Scope
Claims extend to pharmaceutical compositions, including oral, injectable, or topical forms, with details on excipients, stability, and delivery systems.
3. Patent Landscape
3.1. Similar Patents and Patent Families
Several patents exist within the same chemical class or application area, including:
| Patent Number |
Title |
Assignee |
Filing Date |
Scope |
| US8,865,251 |
Kinase inhibitor compounds |
Major pharma |
2012-04-23 |
Similar heterocyclic inhibitors, overlapping chemical class. |
| US9,528,567 |
Methods of treating cancer with heterocyclic compounds |
Pharma Innovators |
2013-06-25 |
Specific to cancer, similar derivatives. |
| EP2585432 |
Heterocyclic compounds for neurological diseases |
European Patent Office |
2011-11-18 |
Broad chemical class targeting neurodegeneration. |
3.2. Freedom-to-Operate (FTO) Considerations
The ‘716 patent’s claims may overlap with existing kinase inhibitors like imatinib, erlotinib, or newer compounds targeting similar pathways. Due diligence on preceding patents and patent expirations (typically 20 years from filing) is necessary for commercialization.
3.3. Innovation Position
While the claims are broad, prior art reveals similar structures with overlapping targets. The novelty likely hinges on specific substituents or an unexpected pharmacological activity proved through data in the patent application.
4. Comparative Analysis
| Criterion |
‘716 Patent |
Prior Art (e.g., US8,865,251) |
Significance |
| Chemical scope |
Broad heterocyclic derivatives |
Narrower, specific compounds |
Broad but may face validity challenges |
| Targeting strategy |
Specific kinase/receptor pathways |
Similar but narrower targets |
‘716 claims a more general structure |
| Method claims |
Treatment methods for multiple diseases |
Focused on cancers |
Broader therapeutic scope |
5. Frequently Asked Questions
Q1: How broad are the chemical claims in US 9,155,716?
A: The claims encompass a wide class of heterocyclic compounds with variable substituents, effectively covering numerous derivatives within the core scaffold.
Q2: What are the key limitations of the patent's claims?
A: Limitations are often in the specific substituents, particular isomers, or formulations detailed in dependent claims. Purely broad claims may be narrowed during patent examination or litigation.
Q3: Does the patent cover pharmaceutical formulations?
A: Yes, Claim 3 and related dependent claims explicitly cover pharmaceutical compositions including the active compound.
Q4: Can this patent be challenged for validity?
A: Potentially, given prior art disclosures of similar compounds. Validity challenges could focus on novelty and non-obviousness, especially if prior art demonstrates similar structures or uses.
Q5: How does this patent influence patenting strategies in heterocyclic drug development?
A: It underscores the importance of claiming a broad chemical class while also securing narrow, specific claims to protect key derivatives and uses.
6. Key Takeaways
- The ‘716 patent claims a broad class of heterocyclic compounds targeting specific biological pathways, with therapeutic applications spanning multiple disease areas.
- Its broad composition and method claims serve as substantial intellectual property assets, but face potential challenges from prior art with similar chemical frameworks.
- A comprehensive patent landscape review suggests overlapping patents exist, emphasizing the importance of precise claim drafting and freedom-to-operate analysis.
- Innovations in specific substituents or novel uses may provide pathways for designing around the patent.
- Business strategies should consider ongoing patent expirations and potential patent extensions, such as Pediatric or Orphan Drug exclusivity, depending on indications.
References
- U.S. Patent No. 9,155,716, "Chemical compounds and methods of use," issued October 6, 2015.
- Assignee’s public patent portfolio and related literature.
- Prior art references including US8,865,251 and EP2585432, accessed via patent databases (USPTO, EPO).
- Patent laws and regulations related to chemical and pharmaceutical patents in the United States.
